- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration, Magnetic Resonance Imaging
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- cabozantinib-s-malate, fluorine F 18 d-FMAU, positron emission tomography, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cardiac Amyloidosis
- Interventions
- [18F]Fluselenamyl (FSA)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Normal Controls, MCI
- Interventions
- the radiotracer 18F-AV-1451
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant, Glioma Intracranial
- Interventions
- 18F-Fluciclovine
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Interventions
- 18F-fluciclovine, PET/CT
- Drug · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Tumor, Recurrent, Adult
- Interventions
- PET/CT with F-Fluciclovine (Axumin)
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Renal Cell Carcinoma
- Interventions
- 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography, Sunitinib
- Drug · Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut
- Conditions
- Secondary-progressive Multiple Sclerosis
- Interventions
- Mayzent, Ocrevus
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Metastatic Neoplasm
- Interventions
- MK-8294, CD8 PET Tracer
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Hackensack, New Jersey • Houston, Texas
- Conditions
- Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
- Interventions
- [Ga-68]MTP220 PET/CT Scan
- Drug
- Lead sponsor
- Qiubai Li
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- Nathan Denlinger
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls
- Interventions
- C11-SY08
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine, N-13 ammonia
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Encinitas, California • Irvine, California • La Jolla, California + 12 more
- Conditions
- Healthy Adults
- Interventions
- Dextroamphetamine, Placebo, [18F]Fallypride, [18F]-FE-PE2I
- Drug · Diagnostic Test
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alzheimer Disease
- Interventions
- 11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 52
- States / cities
- Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
- Conditions
- Alzheimer's Disease
- Interventions
- I123MNI388/I123MNI390
- Drug
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostatic Neoplasms
- Interventions
- Gallium-68 citrate, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California